


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS:

1. (Original): A compound of the formula



wherein R¹ is fluoro;

s is three;


R² is (C₃-C₆)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C₁-C₄)alkyl, hydroxy, (C₁-C₆)alkoxy, and (C₁-C₆)alkyl-(C=O)-O-;

or a pharmaceutically acceptable salt thereof.

2. (Canceled).

3. (Currently Amended): A compound according to claim 2 1, wherein R² is optionally substituted cyclopropyl or cyclobutyl.

4. (Original): A compound according to claim 3, wherein the compound has the formula



1c

5. (Original): A compound according to claim 4, wherein R² is (C₃-C₆)cycloalkyl.
6. (Original): A compound according to claim 4, wherein R² is (C₃-C₆)cycloalkyl substituted with one or two (C₁-C₃)alkyl.
7. (Original): A compound according to claim 4, wherein R² is (C₃-C₆)cycloalkyl substituted with one or two methyl groups.
8. (Original): A compound according to claim 4, wherein R² is (C₃-C₆)cycloalkyl substituted with one (C₁-C₃)alkyl.
9. (Original): A compound according to claim 4, wherein R² is (C₃-C₆)cycloalkyl substituted with one methyl, ethyl or propyl group.
10. (Canceled).

11. (Withdrawn): A method of treating an MAP kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

12. (Withdrawn): A method of treating a p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

13. (Withdrawn): A method for treating a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 effective in treating such a condition.

14. (Withdrawn): A pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

15. (Withdrawn): A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of MAP kinase in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

16. (Withdrawn): A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of p38 kinase in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

applying the stimulus to the device to generate a second set of responses, each of said second sets of responses one or more events of a second series of events, said second series of events occurring simultaneously with said first series of events;

receiving the first and second sets of responses from the device; ~~and~~

processing the received first and second sets of responses to distinguish said first series of events from said second series of events, and to separate the responses due to said environmental factor from the responses due to the stimulus and to identify the responses due to the stimulus.

9. (Original) A method according to Claim 8, wherein:

the electronic device is an integrated circuit including a multitude of individual switching circuits;

said environmental factor causes at least some of said switching circuit to emit photons; and

the timing signal causes at least some of said switching circuits to emit photons.

10. (Currently Amended) A method ~~according to Claim 9;~~ of processing timing information with respect to a stimulus applied to an electronic device, comprising the steps of:

locating the electronic device in a given environment including at least a first environmental factor causing the electronic device to generate a first set of responses;

applying a stimulus to the device to generate a second set of responses;

receiving the first and second sets of responses from the device; and